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Abstract 
Urinary biomarkers of plant food supplement (PFS) exposure/ intake represent 
an accurate, non-subjective tool for determining PFS consumption in humans 
with applications ranging from epidemiology to subject compliance in clinical 
trials.  Ginkgo biloba remains one of the worlds most popular PFS, yet few studies 
have investigated the uptake and metabolism of its primary unique bioactives: 
the terpene lactones. To this end, we conducted a dual-dose, acute crossover 
intervention using Ginkgo biloba supplements in healthy participants (n=12). 
Pooled 24-hr urine samples were analysed by triple quadrupole LC-MS-MS. We 
observed that bilobalide, and ginkgolides A and B were passed into urine intact 
and in a dose-dependent manner. Low levels of intact ginkgolides C and J were 
also excreted. To our knowledge, this is the first study to report intact ginkgolide 
J in urine following oral consumption of ginkgo supplements, and is also the first 
to account for excreted terpene lactones as a proportion of dose.  
 
Introduction 
Ginkgo biloba (ginkgo, also referred to as Maidenhair tree) has a long history of 
phyto-medicinal use, and is of high commercial significance to the worldwide 
plant food supplement (PFS) market. It has an association with Chinese herbal 
medicine dating back 5000 years, with its use as a medical treatment for senility 
being first recorded over 500 years ago (1). More recent evidence links ginkgo 
principals to several promising properties, including anti-platelet activity (2), 
improved nitric oxide availability (3), wound healing (4), anti-asthmatic activity 
(5) and neuroprotection (6).  However the evidence from randomized controlled 
human interventions is less clear, and recent systematic reviews and meta-
analyses of Ginkgo efficacy in the areas of cognition in dementia (e.g. Weinmann 
et al. (7); vs. Birks & Evans (8)) and tinnitus management (e.g. von Boetticher 
(9); vs. Hilton et al. (10)) are contradictory in their conclusions. Deficiencies in 
intervention design are a major driver of this controversy. Nevertheless, Ginkgo 
remains one of the worlds most popular PFS, with combined sales from France, 
Germany, UK, US, Japan and China worth approximately half a billion dollars (US) 
in 2011 alone (11).  
 
The accurate determination of individual PFS intake is vital for related efficacy 
research. Urinary biomarkers of PFS exposure/ intake can be used to rapidly 
(and often retrospectively) gauge the intake of large cohorts, assess subject 
compliance in clinical trials, and quantify the bioavailability of active principals 
from different PFS preparations. This typically involves collecting urine, either 
over a 24-hour period or “spot” urine as a single sample, and measuring one or 
more representative metabolites in the sample using appropriate methodology. 
However, the identification of specific biomarkers of intake can be complicated 
by wide inter-individual variation in the uptake and metabolism of ingested 
compounds from the PFS of interest, and by the occurrence of the same 
compounds in other foods, beverages and supplements.  
 
High quality Ginkgo PFS products are commonly based on standardised leaf 
extracts, such as EGb 761 (Dr. Wilmar Schwabe GmbH & Co.) or LI 1370 
(Lichtwer Pharma AG). The German Commission E monograph on Ginkgo 
requires that such extracts contain less than 5ppm ginkolic acids, a flavonol 
glycoside content of 22-27% and a terpene lactone content of 5-7%.  Capillary 
LC-ITMS fingerprint analysis of commercial Ginkgo extracts showed that of 72 
tentatively identified flavonoids, 42 were glycosides of the flavonols quercetin, 
isorhamnetin and kampferol (12). Following hydrolysis to the aglycone forms, 
these 3 compounds can easily be quantified by HPLC-UV, however, routine use of 
flavonol aglycone content as a raw material quality indicator may facilitate 
adulteration (13). The terpene lactones, including the Ginkgolides (A,B, C and J, 
see figure 1) and Bilobalide (figure 2), can be observed at 220 nm, however 
response and selectivity is too poor for HPLC analysis (14). Whilst a wide range 
of improved analytical techniques for Ginkgo terpenes are now available (for 
review see (15)), LC-MS has become a well-utilised technique for analysis in 
biological matrices. Several authors have reported on the pharmacokinetics of 
terpene lactones in plasma following Ginkgo consumption (16-18) however to 
date the majority of studies considering urinary derivatives have focused on the 
flavonols (19) and their common downstream metabolites (20).  
 
Quercetin, isorhamnetin and kampferol are not unique to Ginkgo biloba, being 
widely found in foods such as onions, red wine, tomatoes and tea. As such, the 
specificity of these flavonols would be insufficient to quantitatively determine 
ginkgo intake within participants consuming an open diet. Therefore, we 
investigated the utility of terpene lactones as urinary biomarkers of ginkgo 
intake via an acute randomized, 2-dose crossover intervention study.   
 
Experimental Procedures 
Reagents and Reference Materials 
All solvents (methanol, ethanol, ethyl acetate) were of HPLC grade or higher, 
obtained from VWR. LC-MS grade water was produced using a combination 
Elix/MilliQ purification system (Millipore, UK). Sodium azide (>99%) and EDTA 
(>98.5%) were obtained from Sigma (UK). Reagent grade ascorbic acid was 
obtained from Extrasynthese (France) 
 
All reference standards were of HPLC grade (>95%). Taxifolin was obtained from 
Extrasynthese (France). Ethyl gallate was obtained from Apin Chemicals (UK). 
Reference standards for bilobalide and ginkgolides A, B, C and J were kindly 
provided by Phytolab (Germany).  
 
Participants 
This open oral intervention was carried out within the School of Food Science 
and Nutrition, University of Leeds, UK. Approval was granted by the University 
ethics committee (MEEC 09-019), and the study adhered to Declaration of 
Helsinki principles. Volunteers were required to sign a consent form, and 
complete a medical questionnaire. A total of 12 healthy volunteers were 
recruited, aged 23-26 years, comprising 5 males and 7 females, with an average 
BMI of 23.5±7 Kg/m2. Exclusion criteria included i) any significant medical 
complaint, ii) history of surgery of the gastrointestinal tract, iii) any diseases that 
might influence the rate/degree of PFS uptake, iv) drug allergies pertinent to the 
PFS of interest, v) routine use of medication, traditional herbal medicine or other 
plant-based supplements.  
 
Study Design 
The intervention was a dual dose, crossover study, in which participants were 
randomly allocated to consume either 1 or 2 x 500 mg tablets at a single sitting 
(in line with manufacturers dosage instructions). Each intervention stage 
required participants keep to a polyphenol-free diet for 48 hrs, avoiding tea, 
coffee, alcohol, fruit and vegetable derived foods, chocolate, and high bran cereal 
derived foods such as brown bread, whole grain breakfast cereals and brown 
rice. At the end of the first 24 hrs, a urine sample was collected as a compliance 
measure. The intervention dose was then consumed, and urine was collected as a 
24hr pool. After completion of the 24 hr pool, participants were free to cross 
over to the next intervention stage.  
 
Urine was collected in clean, dry, 3 L polypropylene vessels (Urisafe, obtained 
from VWR, UK), each containing a 3 g aliquot of ascorbic acid powder to act as a 
preservative. Filled vessels were kept cool and dark, and collected the day after 
use. The weight and volume of urine was noted, and following homogenisation, 3 
x 10 ml aliquots were placed in 15 ml centrifuge tubes (BD Biosciences, UK). A 
100 l aliquot of sodium azide solution (10% w/v) was added to each tube as an 
anti-bacterial agent. The tubes were vortexed (10 sec) then stored at -20°C until 
extraction.  
 
Analysis of Ginkgo Supplements 
Supplements were from Boots UK Ltd., branded “Ginkgo Biloba Brain Health” 
tablets. Each disk shaped compressed 500 mg tablet was stated to contain 120 
mg of ginkgo biloba extract, standardised to provide 28.8 mg of flavonol 
glycosides and 7.2 mg of terpene lactones. Tablets were obtained from a local 
pharmacy, and 2 distinct batches were utilized during the human intervention, 
designated batch 1 (#141015), and 2 (#141941). From each batch, 2 tablets 
were weighed and then individually crushed using a pestle and mortar. From 
each powdered tablet an aliquot of approximately 10 mg was accurately weighed 
into a 1.5 ml centrifuge tube (Eppendorf, UK). To each aliquot 1 ml of extraction 
solvent was added, comprising aqueous ethanol (50% v/v), ascorbic acid (0.1% 
w/v) and taxifolin as internal standard (10 g/ml). The mixture was vortexed 
(30 sec), placed in an ultrasonic water bath (30 min) then vortexed again to 
extract soluble materials. The tubes were then centrifuged at 17,000 R.C.F. (10 
min; Thermo Scientific, UK) and the supernatant removed. A second 1 ml aliquot 
of extraction solvent was added to the pellet, and the process extraction 
repeated. A 1 in 10 dilution of the 1st extract was made using extraction solvent, 
and all 3 samples (per tablet) were analysed via LC-MS. Typically 96.6% of target 
analytes were present in the first extract.  
 
Analysis was conducted on a Shimadzu LC-MS system comprising a Nexera 
UHPLC (with binary pump, autosampler set to 8°C, and column oven set to 35°C) 
and an LC-2020 single quadrupole mass spectrometer. A 5 l sample aliquot was 
injected onto a Kinetix C18 XDB 150x2.1 2.6 m column (Phenomenex UK) fitted 
with a low volume “Krud catcher” pre-filter. Samples were separated on a binary 
gradient of aqueous LC-MS grade methanol (5 versus 95% v/v, solvents A and B 
respectively) plus 0.1% formic acid (v/v) running at a flow rate of 0.3 ml/min.  
The gradient was held at 8% solvent B for 5 min, then increased linearly to 40% 
over 15 min, up to 90% in 2 min, was held for a further 2 min, then decreased to  
8% over 2 min and was re-equilibrated over 8 min. The first 3 min of each run 
was diverted to waste. The MS ran with an interface temperature set to 350°C, 
using nebuliser and drying gas flow rates of 1.5- and 15L/min, respectively. The 
analysis was performed in negative SIM mode, optimized using reference 
standards. Bilobalide and taxifolin internal standard were followed on m/z 325.1 
and 303.1 respectively. In addition to m/z equivalent to [M-1]-, the ginkgolides 
also formed persistent formate adducts, i.e. [M + 45]-, which were also followed. 
Hence ginkgolides A, B, C and J were quantified / qualified on m/z 453.2/407.2, 
423.1/469.1, 439.1/485.1 and 469.1/423.1, respectively. Peak areas were 
normalized to internal standard, and analytes quantified via a log:log standard 
curve plot ranging 0.1-10 g/ml. 
 
Analysis of Participant Urine 
Urine samples were defrosted at room temperature immediately before 
extraction, placed in an ultrasonic water bath (5 min) then vortexed (30 sec) to 
ensure homogeneity. Each urine sample was extracted in triplicate. Each 200 L 
aliquot of urine was combined with 20 L of an aqueous solution of ascorbic acid 
(1% w/v) and EDTA (0.1% w/v), 100 L of ethanol containing 2 g/ml ethyl 
gallate (IS1) and 1 ml of ethyl acetate in a 1.5 ml centrifuge tube. The solution 
was vortexed, placed in an ultrasonic water bath and vortexed again to extract 
soluble material. The tubes were centrifuged at 17,000 R.C.F. (10 min) and the 
upper layer removed. A second 1 ml aliquot of ethyl acetate was added to the 
pellet, and the extraction procedure repeated. All extracts were dried under 
nitrogen at room temperature and frozen at -20°C. On the day of analysis, the 
second extracts were reconstituted with 70 l of ethanol, vortexed, placed in an 
ultrasonic water bath and vortexed again. A 50 l aliquot of the reconstituted 
second extract was combined with the corresponding first (dried) extract, which 
was similarly vortexed and sonicated. A 50 l aliquot of ascorbic acid solution 
(0.2% w/v) containing taxfolin (IS2) at 8 g/ml was added to the combined first 
and second extract, which was then vortexed and centrifuged. The supernatant 
was placed in an amber 300 l HPLC vial, which was capped and kept at 8°C until 
analysis.  
 
A modified sample preparation method was developed to prepare polar material 
for pilot analyses, wherein ethyl acetate was substituted for methanol. Methanol 
was removed from the samples using an EZ2+ centrifugal evaporator (Genevac, 
UK) using the HPLC drying program for 1 hr. Water was subsequently removed 
from the samples via freeze drying at -50°C for 24 hrs. Reconstitution occurred 
as described above.  
 
Analysis was conducted on an Agilent LC-MS-MS system comprising a 1200 SL 
binary pump, well plate autosampler set to 8°C, and column oven set to 35°C, 
connected to a 6410a triple quadrupole mass spectrometer. Each 5 l sample 
was separated via the same chromatographic method detailed above.  The first 3 
min of each run was diverted to waste, and thereafter directed into the MS 
interface set to 350°C, using nebuliser pressure of 30 psi and drying gas flow 
rates of 11 L/min. The analysis was performed in negative MRM mode, 
optimized using reference standards. The following m/z transitions were used 
for quantification / qualification purposes: ethyl gallate (IS1), 
197.1>124.0/169.1; taxifolin (IS2), 303.1>285.0/125.0; bilobalide, 
325.1>163.1/251.1; ginkgolide B, 423.2>367.2; ginkgolide C, 439.2>383.2. 
Ginkgolide A formed a persistent formate adduct and was followed on a 
transition of 453.2>351.2/407.1. Ginkgolide J did not fragment in the collision 
cell, and was thus followed on a SIM of m/z 423.2. The standard curve was 
produced by spiking blank urine (made from a 12 participant homogenate of 
baseline urine) with reference standards to a final concentration range of 0.01-
100 M. Each sample was then handled as for the ethyl acetate preparation 
protocol described above, and each curve point was produced in triplicate. Peak 
areas were normalized to IS2, and analytes quantified via a log:log standard 
curve plot. The limit of quantification (LOQ) was below 500 nM for bilobalide 
and ginkgolide J, below 50 nM for ginkgolide A and below 10 nM for ginkgolides 
B and C. Total terpene lactones excreted post-supplementation was calculated as 
mol in total volume of 24 hr pooled urine. 
 
The MS parameters of the above method were adapted to enable investigation 
into possible phase 2 terpene lactone conjugates. MRM parameters matching 
anticipated compounds can be observed in tables 1 and 2.  
 
Results  
Supplement Analysis 
On average, each tablet weighed 517.0 ± 5.5 mg. Tablets in batch 1 delivered 7.9 
± 0.1 mg of target ginkolides and bilobalide, whilst batch 2 tablets delivered 8.0 ± 
0.2 mg, equivalent to 20.3 ± 0.3 and 20.7 ± 0.4 mol. This marginally exceeded 
the 7.2 mg of terpene lactones per tablet stated by the manufacture.  As can be 
seen in figure 3, on a molar basis bilobalide was the single largest contributor to 
the terpene lactone profile at 7.8 ± 0.2 mol per capsule, with ginkgolides A B 
and C making roughly equal contributions. Ginkgolide J was a comparatively 
minor contributor to the overall terpene lactone profile.  
 
Urinary biomarker analysis 
Separation of target analytes in urine can be seen in figure 4. Elevated levels of 
terpene lactones compared to baseline indicated 100% compliance in all 
participants, regardless of randomization order. However, it is possible that the 
minimum 24 hr wash out was slightly too short to ensure complete clearance of 
all target compounds in all participants, as very low levels of terpene lactones 
could be observed in the baseline urine of 7 volunteers at the start of the second 
dose. In the majority of cases this was judged not to influence the outcome of the 
study: total terpene lactone concentrations at baseline ranged just 0.01-0.3% 
that of the post-supplement concentrations. However in 3 individuals, baseline 
terpene lactone concentrations equated 2-6% that of the corresponding post-
supplement urine. As such, statistical analysis was performed both including and 
excluding these 3 individuals.  
 
For the full n=12 group, average total terpene lactones excreted were 7.5±2.6 
mol following low dose ginkgo, and 17.1 ±3.6 mol following high dose 
supplementation (see figure 5) indicating a dose-dependent excretion of 
analytes. Average low versus high dose excretion of individual compounds were 
as follows: bilobalide, 2.4±0.8 mol vs 5.3±2.1 mol; ginkgolide J 21.6±29.3 nmol 
vs. 171.7±85.7 nmol; ginkgolide C, 119.8±45.7 nmol vs. 318.2±124.0 nmol; 
ginkgolide A, 3.8 ± 0.4 mol vs. 8.7±2.1 mol; ginkgolide B, 1.1±0.4 mol vs. 
2.7±0.7 mol.  All increases for individual terpene lactone excretion with dose 
were statistically significant, returning p-values of >0.01 for both paired 2-tail t-
tests and single factor anova tests. Removal of data from the 3 flagged washout 
subjects did not diminish the strength of this statistical significance, except in the 
case that a paired 2-tail t-test for bilobalide excretion returned p=0.011.  
 
In line with a dose-dependent excretion of compounds, the percentage of the 
initial dose recovered in urine was similar between low and high dosing, with 
total terpene lactone recoveries of 37±13 % and 42±9%, respectively. However, 
there was a marked difference between the recoveries of each individual 
compound (see figure 6). At high dose, 34±14% and 36±10% of bilobalide and 
ginkgolide B were recovered intact in urine, respectively. However, only 8±4 % 
and 4±2 % of the high dose were recovered for ginkgolides J and C. The 
calculated recovery of ginkgolide A was 109±26%, ranging from 57% to 149%.  
 
Pilot phase 2 conjugate identification 
Following successful identification of intact ginkgolides in urine, a further 
exploratory investigation was performed to seek classical phase 2 metabolites, 
namely sulfates, glucuronides and methylated forms. However, MRM 
experiments, based on anticipated post-collision compound fragmentation, did 
not identify any potential conjugates produced at a level approaching that of the 
intact ginkgolides, with no signals observed in non-polar solvent-extracted urine. 
However, in urine prepared via a polar inclusive method, a small transition 
return was observed corresponding to a possible methylated bilobalide 
(339>163, retention time 20.4 min) with approx 30% relative peak area of 
bilobalide itself. Whilst methylation would increase non-polarity and thus 
retention on a C18 bonded phase, the retention of this analyte is almost double 
that of proposed parent (10.9 min). The identity of this relatively minor 
compound therefore requires further clarification.  
 
Discussion 
The uptake and metabolism of flavonols from plant foods is well established. For 
example, quercetin is typically the most abundant flavonol in commercial gingko 
extracts (13), but exists as a variety of glycosides of which rutin (querecetin-3-O-
rhamnoglucoside) is a major form. Rutin is not significantly absorbed in the 
small intestine, requiring cleavage via colonic glycosidases before uptake in the 
large intestine (21). Upon absorption, quercetin can be metabolised both within 
the epithelial cells and in the liver to form methlyated, glucuronidated and 
sulphated metabolites, which are the forms present in circulating plasma and 
urine (22). Typically, the proportion of the dose appearing in urine is quite low. 
For example following consumption of fried onions by volunteers (n=6), the 
recovery of all quercetin, kaempferol and isorhamnetin conjugates in 24 hr urine 
equated to 4.7% of the dose (23). Both quercetin and kaempferol have been 
identified intact in human urine following ginkgo extract consumption (24, 19). 
Pietta et al. (20) also observed a variety of conjugated phenolic acids in urine 
following ginkgo extract consumption in humans, of which 3,4-dihydroxybenzoic 
acid represented the most abundant compound present in post-supplement (but 
not baseline) urine.  
 
Comparatively fewer studies have addressed the uptake of terpene lactones from 
Ginkgo biloba in humans, the majority of which have focussed on the major forms 
and concentrations found in plasma. For example, in a pharmacokinetic study by 
Kressman et al. (17), healthy male volunteers (n=12) consumed 2 x ginkgo 
supplement tablets, each containing 60 mg of EGb761 extract that provided 
2.0±0.7, 1.0±0.2 and 5.8±2.8 mol/tablet of gingkgolide A, ginkgolide B and 
bilobalide respectively, the total dose being similar to that of our low dose 
condition. The average plasma Cmax for gingkgolide A, ginkgolide B and bilobalide 
was 54.4±11.2, 19.5±4.3 and 166.8±41.7 nM respectively, with tmax achieved at 
1.2, 1.5 and 1.2 hr (16 hr follow up) indicating all 3 compounds are primarily 
absorbed in the small intestine. This data is consistent with typical plasma Cmax 
and tmax values achieved following consumption of 3 commercial ginkgo 
preparations by 24 volunteers (18). Ginkgolide C has been reported as absent in 
plasma for both humans (16) and guinea pigs (25) following oral administration 
of ginkgo extract. The oral bioavailability of ginkgolides from extracts is related 
to the rate of supplement dissolution at low pH (17) and can be improved via 
complexation with soy phospholipids (16).   
 
To our knowledge, only one other study has investigated the presence of ginkgo 
terpene lactones in human urine. Following consumption of a single tablet stated 
to contain 7.2 mg terpene lactones, average concentrations of gingkgolide A, 
ginkgolide B and bilobalide were 4.1±0.8, 1.5±0.3 and 4.8±0.7 M, respectively in 
urine collected up to 4 hr post-intervention (n=5, ± SD; (26)).  These values are 
consistent with typical concentrations in our study from 24 hr pooled urine 
following low dose ginkgo, with concentrations of 5.9±2.1, 1.7±0.5 and 4.2±1.6 
M (n=12, ± SD) for gingkgolide A, ginkgolide B and bilobalide, respectively. Ding 
et al., also detected Ginkgolide C in urine, albeit at a comparatively lower average 
concentration of 0.2±0.05 M, which again is consistent with an observed post 
low-dose concentration of 0.18±0.06 M from our study.  
 
To our knowledge, ours is the first study to report intact ginkgolide J in urine 
following oral consumption of ginkgo supplements, and is also the first to 
account for excreted terpene lactones as a proportion of dose. The high levels of 
ginkgolide A as a percentage of ingested dose in some individuals, combined 
with a wide inter-individual variability in output is suggestive of additional 
production of this compound in vivo, possibly through a metabolic conversion of 
other ginkgolides. Ginkgolides A-J are differentiated only by the level of 
hydroxylation at positions R1 and R2 (see figure 1). It is therefore feasible that 
that ginkgolides B, C and J could all be converted to ginkgolide A through 
dehydroxylation in vivo, a common step in xenobiotic metabolism. For example, 
following oral administration of pure chlorogenic acid to rats (27) and humans 
(28), subsequent increases in 3-hydroxy cinnamic acid (aka m-coumaric acid) 
were observed in urine. The appearance of this molecule follows a cleavage of 
chlorogenic acid to quinic and caffeic acids and then to 3,4-dihydroxycinnamic 
acid, which can then undergo dehydroxylation. Whilst this type of metabolic 
transformation might explain the apparent low recovery of ginkgolides C and J, 
further mechanistic studies are required to explore this possibility.  
 
Ding et al. (26) previously observed that -glucuronidase and sulfatase enzymes 
had no influence on apparent levels of urinary terpene lactones, which is in line 
with our lack of response for signals relating to classical phase 2 metabolites via 
MRM and also the high excretion of these compounds relative to dose. Similarly 
we did not observe methylated ginkgolide C, previously reported as a new 
species in plasma by Mauri et al. (25) after oral ginkgo supplementation in both 
guinea pigs and human subjects.  It is noted, however, that this new species, 
quantified via SIM on m/z 453, co-eluted exactly with ginkgolide A. In our study 
and that of Woelkart et al. (18), ginkgolide A predominantly formed a formate 
adduct on LC-MS analysis, which also has m/z = 453. Whilst Mauri et al. validated 
the identity of methylated ginkgolide C via its absence in the plasma of animals 
treated with pure bilobalide and ginkgolide B, critically the same validation test 
was not performed for pure ginkgolide A. Therefore, we propose that the identity 
of methylated ginkgolide C is in question.  
 
In conclusion, following the consumption of ginkgo biloba supplements at doses 
relevant to typical consumer use, it is apparent that bilobalide, and ginkgolides A 
and B are i) excreted in urine at sufficient levels to be routinely detectable via 
LC- triple quadrupole analysis and ii) are excreted in a dose-dependent manner. 
Therefore, these compounds are recommended as biomarkers of Ginkgo biloba 
consumption.  
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 TABLES AND FIGURES 
TABLE 1:  MRM parameters of anticipated glucuronide/sulfate terpene lactone 
conjugates 
 
C
o
m
p
o
u
n
d
 
MRM Parent ions MRM 
Daughter 
ions 
Mono 
sulfate 
Di-
sulfate 
Mono 
glucuronide 
Di-
glucuronide 
Sulfate-
glucurnoide 
GA 
533.2 
487 
613.2 
567 
629.2 
583 
805.2 
759 
709.2 
663 
453.2 
407 
GB 503.2 583.2 599.2 775.2 679.2 423.2 
GC 51932 599.2 615.2 791.2 695.2 439.2 
GJ 503.2 583.2 599.2 775.2 679.2 423.2 
BIL 405.1 485.1 501.1 677.1 581.1 325.1 
 
TABLE 2:  MRM parameters of anticipated methylated glucuronide/sulfate 
terpene lactone conjugates 
 
C
o
m
p
o
u
n
d
 
MRM Parent ions 
MRM 
Daughter 
ions 
MRM 
Parent 
ions 
MRM  
Daughter         
ions 
Methylated 
mono- 
sulfate 
Methylated 
mono- 
glucuronide 
Mono-
methyl 
conjugate 
GA 
547.2 
501 
643.2 
597 
467.2 
421 
467.2 
421 
351/365/421/407 
351/365 
GB 517.2 613.2 437.2 437.2 367/395/381/409 
GC 533.2 629.2 453.2 453.2 383/397 
GJ 517.2 613.2 437.2 437.2 367/395/381/409 
BIL 419.1 515.1 339.1 339.1 163/251/177/265 
 
 
 
  
FIGURE 1: Structure of Ginkgolides 
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Ginkgolide A H H OH 
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FIGURE 2: Structure of Bilobalide 
 
 
FIGURE 3: Profile of average terpene lactone content (mol per capsule, ± S.D.) 
 
 
7.8 
1.1 
3.9 4.0 3.8 
0.0
1.0
2.0
3.0
4.0
5.0
6.0
7.0
8.0
9.0
Bilobalide Ginkgolide J Ginkgolide C Ginkgolide A Ginkgolide B
A
m
o
u
n
t 
p
er
 t
ab
le
t 
(
m
o
l)
 
FIGURE 4: LC-MS-MS Total ion count chromatogram of terpene lactones in 24 hr 
urine following consumption of 240 mg ginkgo extract (high dose)  
 
Retention times (min) of bilobalide (11.7), ethyl gallate (14.9), ginkgolide J (16.2), 
ginkgolide C (16.9), taxifolin (17.3), ginkgolide A (20.5) and ginkgolide B (21.2)  
 
FIGURE 5: Terpene lactones excreted within 24 hr at low and high ginkgo doses 
(mol, ±SD; n=12) 
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FIGURE 6: Percentage of terpene lactone dose recovered in 24 hr urine following 
ginkgo consumption (, ±SD; n=12)  
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